Yalda Nikanpour, Post Doctoral Research Fellow in the Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, shared a post on X:
“Our new paper is out! In mCRPC treated with PSMA-RLT, metastatic disease volume emerged as a key driver of outcomes. A simple stratification that could sharpen how we select patients. ”
Title: Prognostic Outcomes of [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in High-Volume and Low-Volume Metastatic Castration-Resistant Prostate Cancer
Authors: Yalda Nikanpour, Geoffrey B. Johnson, Carter A. Day, Wael O. Zeina, Rimki Haloi, Mindie L. Mahon, Lauren A. Rhode, Mohamed E. Ahmed, Eman E. Ahmed, Mahnoor Ashraf, Eugene D. Kwon, Jack R. Andrews.
Read the article here.
Other articles about Metastatic Castration-Resistant Prostate Cancer on OncoDaily.